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February 2018 Letters to the Editor e23occurred in separate cellular clones. The level of the
C797S mutation is expected to be similar to or lower than
the level of the T790M mutation if both mutations are
present in the same cells, and it would show either
concomitant increase or decrease in response to the
combination therapy. The levels of each EGFR mutation
measured by digital droplet polymerase chain reaction
from a series of plasma samples indicated that the
T790M and C797S mutations were likely present in
different tumor cells, a ﬁnding that as we suggested in our
article, may be due to multiple clones with individual
mutations and resultant differences in tyrosine kinase
sensitivity.3
In the blood collected before the combination
therapy, the levels of the T790M and C797S muta-
tions were detected at mutant allele frequencies of
2.8% and 4.5%, respectively. This indicates that the
overall load of C797S-positive tumor was higher than
that of T790M-positive tumor before the combination
therapy. The observed clinical improvement without
reduction in T790M or exon 19 deletion also sup-
ports this hypothesis of clonal heterogeneity
rather than the mutation being present in the same
cells. Deﬁnitive proof, however, would requireDisclosure: The authors declare no conﬂict of interest.
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patient.
Hongdo Do, PhD, Surein Arulananda, M.B.B.S.
Thomas John, M.B.B.S., PhD, FRACP
Alexander Dobrovic, PhD
Olivia Newton-John Cancer and Wellness Center
Heidelberg, Melbourne, Australia
School of Cancer Medicine
La Trobe University
Bundoora, Melbourne, AustraliaReferences
1. Leone A. C797S and T790M EGFR mutations in
non-small-cell lung cancer: in trans or in separate
clones? J Thorac Oncol. 2018;13:e21–e22.
2. Wang Z, et al. Lung adenocarcinoma harboring EGFR
T790M and in trans C797S responds to combination ther-
apy of ﬁrst- and third-generation EGFR TKIs and shifts
allelic conﬁguration at resistance. J Thorac Oncol.
2017;12:1723–1727.
3. Arulananda S, Do H, Musafer A, Mitchell P, Dobrovic A,
John T. Combination osimertinib and geﬁtinib in C797S
and T790M EGFR-mutated non–small cell lung cancer.
J Thorac Oncol. 2017;12:1728–1732.Comments on “Treatment
Strategies and Prognostic
Factors of Limited-Stage
Primary Small Cell
Carcinomaof theEsophagus”To the Editor:
We read with great interest the article by Xu et al.1 After
reading this article carefully and critically, we noticed
some methodological and statistical issues that were
not addressed or mentioned as limitations of the study.
We therefore wish to highlight a few important take-
home messages as follows.First, the study population consisted of patients
who visited and were treated in a tertiary care cen-
ter.2 Here, the validity of the results may be
threatened by selection bias because the recruited
participants comprised a nonrandom sample from
the target population. Such selection bias is deﬁned
as recruitment or referral bias.3 This bias stems
from the fact that patients who participated in
the study may differ from those who did not
participate in the study. For example, people who
are referred to a tertiary care center may have
characteristics (e.g. socioeconomic status) different
from those of people who are not. Therefore, the
estimated survival of patients with primary small
cell cancer of the esophagus may reﬂect a degree of
selection bias.
Therefore, we recommend that the authors report the
background characteristics of the patients in detail. In
addition, they could adjust for the effect of these char-
acteristics on survival by including them in the multi-
variable analysis as confounders. Moreover, there are
statistical methods for conducting bias analysis to
determine how much the results are inﬂuenced by
selection bias.4
e24 Letters to the Editor Journal of Thoracic Oncology Vol. 13 No. 2Second, as a more general principle, the multivariable
model is developed after a univariate screening for
statistically signiﬁcant predictors. We are concerned as
to why the authors did not use univariate analysis for
selecting the signiﬁcant predictors for their multivari-
able model. On the other hand, how they did their
multivariable analysis is unclear. The stepwise method is
a commonly used approach for model building in
biomedical research. It may be argued that the value of
regression coefﬁcients is highly reliant on univariate
prescreening of variables and type of multivariable
analysis.5,6
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Treatment Strategies and
Prognostic Factors of
Limited-Stage Primary
Small Cell Carcinoma of the
Esophagus”
In Response:
We would like to thank Saﬁri et al. for their interest in
our article and for their helpful comments.1 We have
carefully reviewed both the comments and our article
and the following is our response.First, we retrospectively analyzed the data on 152
consecutive patients with limited-stage primary small
cell carcinoma of the esophagus (PSCCE) who received
treatment at the Afﬁliated Cancer Hospital of Zhengzhou
University.2 Saﬁri et al.1 mentioned that the included
patients were treated in a tertiary care center and that
selection bias may exist. This bias may be because the
patients included in our study may differ from those
who did not participate in our study in terms of having
different characteristics, such as socioeconomic status.
Because of the retrospective nature of this study, this
bias cannot be avoided. The People’s Republic of China
is large-population country with thousands of subordi-
nate hospitals, and currently we do not have the infor-
mation for patients with PSCCE in subordinate hospitals.
In this study, only 152 consecutive patients could be
evaluated retrospectively. However, the comment of
Saﬁri et al. could be a valuable starting point for future
research. We are planning to initiate a multicenter study
to collect patient information as comprehensively as
possible in the near future.
Saﬁri et al.1 stated that the authors should have better
reported the background characteristics of the patients in
